Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Screening for hereditary haemocromatosis

    190588_190588.pdf (175.5Kb)
    Access Status
    Open access
    Authors
    Nadakkavukaran, I.
    Gan, E.
    Olynyk, John
    Date
    2012
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Nadakkavukaran, Itty M. and Gan, Eng K. and Olynyk, John K. 2012. Screening for hereditary haemocromatosis. Pathology. 44 (2): pp. 148-152.
    Source Title
    Pathology
    DOI
    10.1097/PAT.0b013e32834e8453
    ISSN
    00313025
    Remarks

    NOTICE: This is the author’s version of a work in which changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication.

    Copyright © 2012 Royal College of Pathologists of Australasia

    URI
    http://hdl.handle.net/20.500.11937/25354
    Collection
    • Curtin Research Publications
    Abstract

    Hereditary haemochromatosis (HH) is a common autosomal recessive disorder of iron overload in Caucasian populations. Clinical manifestations usually occur in individuals homozygous for the C282Y mutation in the HFE gene product and who have developed significant iron loading. Current screening methods can detect affected individuals either prior to or early during disease evolution, enabling early introduction of phlebotomy treatment that can normalise life expectancy. Evaluation of possible iron overload, via measurement of serum transferrin saturation and ferritin level, is the most appropriate initial test for those subjects presenting clinically for evaluation. HFE genotyping, when combined with serum biochemical measurements, defines the presence of likely iron overload and the underlying genetic disorder and is the preferred initial screening modality for families of an affected individual.Definitive proof of iron overload requires measurement of hepatic iron concentration or total iron burden via therapeutic phlebotomy; elevated serum ferritin level alone is not adequate. We now recognise that the natural history of HH is not as discrete as previously believed, because genetic and environmental modifiers of disease penetrance are increasingly identified as influencing the clinical expression of HH. In fact, a minority of C282Y homozygotes develop classical ‘iron overload disease’, although it has recently emerged that the disorder may predispose to breast and colorectal cancer. Uncertainties as to the true clinical impact of the condition at a population level lead to current recommendations of cascade screening of families of affected patients, case-finding in high-risk groups, such as patients with clinical manifestations consistent with the diagnosis, and a high level of clinical awareness in the community to facilitate early diagnosis. Generalised population screening is not presently recommended.

    Related items

    Showing items related by title, author, creator and subject.

    • Diagnosing and preventing iron overload
      Ramanathan, G.; Olynyk, John; Ferrari, P. (2017)
      Absolute or functional iron (Fe) deficiency is an important determinant of anemia in hemodialysis patients and parenteral Fe is routinely used to treat this condition in conjunction with erythropoiesis stimulating agents. ...
    • Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis
      Maker, G.; Siva, B.; Batty, Kevin; Trengove, R.; Ferrari, P.; Olynyk, John (2013)
      AIM: Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is ...
    • Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial
      Ong, S.; Gurrin, L.; Dolling, L.; Dixon, J.; Nicoll, A.; Wolthuizen, M.; Wood, E.; Anderson, G.; Ramm, G.; Allen, K.; Olynyk, John; Crawford, D.; Ramm, L.; Gow, P.; Durrant, S.; Powell, L.; Delatycki, M. (2017)
      © 2017 Elsevier Ltd Background The iron overload disorder hereditary haemochromatosis is most commonly caused by HFE p.Cys282Tyr homozygosity. In the absence of results from any randomised trials, current evidence is ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.